Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Treatment of Migraine Clear all

Conditions: Migraine
Interventions: Eucalyptus Oil Scent, Isopropyl Alcohol Vapors; Other
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Acute Migraine
Interventions: Elismetrep; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 113
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more

Conditions: Migraine Headache
Interventions: Argus Migraine Treatment device; Device
Lead sponsor: The San Francisco Clinical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Migraine
Interventions: BHV-2100, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 60
States / cities: Gilbert, Arizona • Encino, California • Los Alamitos, California + 57 more

Conditions: Migraine Disorders
Interventions: NP101; Drug
Lead sponsor: NuPathe Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more

Conditions: Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Interventions: Rimegepant, Zavegepant; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Episodic Migraine
Interventions: Atogepant, Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more

Conditions: Migraine, Pain, Nausea, Vomiting, Aura
Interventions: Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo; Drug · Other
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina

Conditions: Migraine
Interventions: Eletriptan; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 16
States / cities: Irvine, California • Newport Beach, California • San Francisco, California + 13 more

Conditions: Migraine, Headache
Interventions: Magnesium Sulfate, Metoclopramide 10mg, Prochlorperazine (Compazine) Injection; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Migraine With or Without Aura
Interventions: Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Migraine, With or Without Aura
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 50
States / cities: Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more

Conditions: Migraine Headache
Interventions: LY2590443, Placebo injection, Sumatriptan, Placebo capsule; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Beverly Hills, California • Chula Vista, California • Fresno, California + 16 more

Conditions: Migraine
Interventions: Ubrogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 109
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more

Conditions: Migraine
Interventions: Lasmiditan; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 71
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 62 more

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Dihydroergotamine, Placebos; Drug
Lead sponsor: Satsuma Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more

Conditions: Migraine, Acute Treatment of Migraine
Interventions: Nerivio; Device
Lead sponsor: Theranica; Industry
Eligibility: 12 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chronic Migraine
Interventions: Nerivio; Device
Lead sponsor: Theranica; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lagrangeville, New York

Conditions: Migraine
Interventions: Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Migraine Disorders
Interventions: sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 49
States / cities: Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more

Conditions: Migraine With or Without Aura
Interventions: Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 3,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 95
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more

Conditions: Migraine
Interventions: Placebo ZNS, ZNS; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more

Conditions: Migraine Headache
Interventions: Placebo, Zolmitriptan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 46
States / cities: Phoenix, Arizona • Fresno, California • Fullerton, California + 43 more

Conditions: Migraine With Aura, Migraine Without Aura
Interventions: Dronabinol MDI; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 29
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more

Search by objective public record fields.

Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Study of Low-level Laser Therapy in the Acute Treatment of Migraine

Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

An Acute Migraine Factorial Study

Safety and Efficacy in Adult Subjects With Acute Migraines

Study in Participants With Acute Migraines Headaches

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

Nerivio Long-term Usage in Patients With Migraine

Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

Zomig - Treatment of Acute Migraine Headache in Adolescents

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache